Immunoglobulin for myasthenia gravis
Milverton, J, Schubert, C, Ellery, B, Morona, J, Parsons, J
Record ID 32018000649
English
Original Title:
Application 1566
Authors' results and conclusions:
Overall the evidence was of poor quality. A non-inferiority claim was proposed where immunoglobulin (Ig) was intended to be used for a limited time frame to manage a patient through a crisis or surgery, and has a direct comparator in plasma exchange. Where Ig may be used as an adjunct therapy to immunotherapy or other standard therapeutics (not plasma exchange), there would need to be an additional benefit from the Ig therapy to justify its use.
Details
Project Status:
Completed
Year Published:
2019
URL for published report:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/6D12F0E1B148DA4DCA25837E001808C5/$File/1566_MSAC_Assessment_Report.pdf
English language abstract:
An English language summary is available
Publication Type:
Other
Country:
Australia
MeSH Terms
- Myasthenia Gravis
- Immunoglobulins
- Chronic Disease
- Immunoglobulins, Intravenous
- Neuroprotective Agents
- Plasma Exchange
Keywords
- Intravenous immunoglobulin therapy
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.